Laurus Labs appoints Independent Directors for five years
Laurus Labs Limited appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for a term of five years effective July 2, 2026, during its 21st Annual General Meeting. The meeting ratified the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and approved two interim dividends totaling ₹2 per share for FY26. Shareholders also re-appointed Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava as Directors and approved remuneration for Non-Executive Directors and Cost Auditors.
*this image is generated using AI for illustrative purposes only.
Laurus Labs Limited appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for a term of five years effective July 2, 2026. The 21st Annual General Meeting (AGM), held via video conferencing, also ratified the adoption of audited financial statements for the financial year ended March 31, 2026, and approved two interim dividends totaling ₹2 per share for FY26.
The meeting ratified the first interim dividend of ₹0.80 per share and the second interim dividend of ₹1.20 per share, both paid for the financial year 2025-26. Shareholders approved the payment of remuneration to Non-Executive Directors, including Independent Directors, and the remuneration payable to Cost Auditors for the financial year ending 2026-27. Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava were re-appointed as Directors, having retired by rotation.
Dr. Shekhar Chintamani Mande (DIN: 10083454) and Ms. Sutapa Banerjee (DIN: 02844650) are not related to any of the Directors or Key Managerial Personnel of the company. Based on their declarations, they are not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. The appointment of Ms. Banerjee received 91.65% votes in favour.
The remote e-voting facility, provided by National Securities Depository Limited (NSDL), was open from June 29, 2026, to July 1, 2026. A total of 1,189 members participated in the e-voting process. The meeting commenced at 3:00 p.m. IST and concluded at 3:57 p.m. IST. Mr. Y. Ravi Prasada Reddy, Proprietor of M/s RPR & Associates, served as the Scrutinizer for the voting process.
| Resolution | Type | Votes For (%) | Votes Against (%) |
|---|---|---|---|
| Adoption of Financial Statements | Ordinary | 99.75 | 0.25 |
| 1st Interim Dividend (₹0.80/share) | Ordinary | 99.99 | 0.00 |
| 2nd Interim Dividend (₹1.20/share) | Ordinary | 99.99 | 0.00 |
| Re-appointment of Mr. Krishna Chaitanya Chava | Ordinary | 99.28 | 0.71 |
| Re-appointment of Mrs. Soumya Chava | Ordinary | 99.28 | 0.71 |
| Appointment of Dr. Shekhar Chintamani Mande | Special | 99.99 | 0.00 |
| Appointment of Ms. Sutapa Banerjee | Special | 91.65 | 8.34 |
| Remuneration to Non-Executive Directors | Ordinary | 88.85 | 11.14 |
| Remuneration to Cost Auditors | Ordinary | 99.99 | 0.00 |
Historical Stock Returns for Laurus Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.10% | +2.80% | +8.12% | +57.54% | +94.67% | +147.18% |
How will the expertise of the newly appointed Independent Directors influence Laurus Labs' strategic direction over the next five years?
What is the company's capital allocation strategy regarding dividends given the approval of two interim dividends for FY26?
Will the significant dissent on remuneration for Non-Executive Directors lead to a review of the company's executive compensation policies?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
